Actively Recruiting

Phase 4
Age: 19Years +
All Genders
NCT07471867

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Led by Yonsei University · Updated on 2026-04-24

100

Participants Needed

1

Research Sites

118 weeks

Total Duration

On this page

Sponsors

Y

Yonsei University

Lead Sponsor

J

Jeil Pharmaceutical Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.

CONDITIONS

Official Title

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 19 years or older at the time of providing informed consent.
  • Patients with Chronic Coronary Syndrome (CCS) who have undergone Percutaneous Coronary Intervention (PCI) and agreed to participate in the study.
  • Patients who are required to maintain dual antiplatelet therapy (DAPT) including clopidogrel for at least 6 months after PCI.
  • Patients who have voluntarily provided written informed consent to participate in this clinical study.
Not Eligible

You will not qualify if you...

  • History of hypersensitivity to P-CABs, PPIs, benzimidazoles, aspirin, clopidogrel, or any excipients in the study drugs.
  • History of or planned surgery affecting gastric acid secretion, such as upper gastrointestinal resection, acid suppression surgery, or gastric mucosal resection (except certain simple surgeries like stomach or duodenum perforation repair, appendectomy, cholecystectomy, hysterectomy, or benign tumor resections).
  • Diagnosis of Zollinger-Ellison syndrome or inflammatory diseases like pancreatitis or inflammatory bowel disease (Crohn's disease or ulcerative colitis).
  • Currently receiving HIV protease inhibitors (atazanavir, nelfinavir) or rilpivirine-containing products.
  • Abnormal blood chemistry within 4 weeks before screening: AST, ALT, ALP, or total bilirubin greater than 3 times the upper limit of normal; or estimated glomerular filtration rate (eGFR) under 30 mL/min/1.73m².
  • Use of medications expected to affect study results, such as other P2Y12 inhibitors besides prescribed clopidogrel, within 2 weeks before baseline.
  • Pregnant or lactating women, or women with a positive pregnancy test.
  • Patients with hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Yongin Severance Hospital, Yonsei University

Yongin-si, Gyeonggi-do, South Korea, 16995

Actively Recruiting

Loading map...

Research Team

Y

Yongcheol Kim, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here